University of Michigan Rogel Cancer Center: Lymphoma trials

The registry lists 16 Lymphoma studies with University of Michigan Rogel Cancer Center as lead sponsor. 1 are open to participants now and 4 have results posted.

Early Phase 1 1Phase 1 6Phase 2 10No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Living Well With LymphomaRecruitingNCT06047626Not applicable
• Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell LymphomasCompletedNCT02158975Phase 2Results posted
• Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular LymphomaTerminatedNCT01389076Phase 2Results posted
• Pilot Study of dMRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B-cell LymphomaTerminatedNCT00645359Results posted
• Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan RegimenCompletedNCT00556452Phase 1/2Results posted
• Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent LymphomaTerminatedNCT04431635Phase 1
• Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell LymphomaWithdrawnNCT03617484Phase 2
• Pacritinib in Relapsed/Refractory Lymphoproliferative DisordersTerminatedNCT03601819Phase 1
• Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell LymphomaWithdrawnNCT03235869Early Phase 1
• Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)WithdrawnNCT02677948Phase 1/2
• Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory LymphomaCompletedNCT02613598Phase 1
• Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in LymphomaWithdrawnNCT01528865Phase 1/2
• Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the BloodCompletedNCT00146055Phase 2
• Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the BloodTerminatedNCT00143884Phase 2
• Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's LymphomaCompletedNCT00143871Phase 2
• Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's LymphomaTerminatedNCT00141700Phase 2